Nicotinic Receptors and Schizophrenia
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Blood Levels of Drug
研究概览
简要总结
The study determines if a new preparation of a drug designed to treat schizophrenia is more slowly released into the body.
详细描述
3-2,4 dimethoxybenzylidene will be compounded with a methyallose compound in doses of 150 and 300 mg. The capsules will be administered singly and eventually bid to determine if sustained blood levels comparable to steady state blood levels seen in previous studies can be determined. Safety and EEG effects will be measured.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers: males and females who are incapable of pregnancy
排除标准
- •Medical illnesses requiring acute treatment
- •History of seizures
- •Substance abuse including nicotine
研究组 & 干预措施
Pharmacokinetic
This single arm examines the pharmaco-kinetics of the release of 3-2,4 dimethoxy-benzilidene anabaseine in a hypomellose sustained release formulation.
干预措施: Pharmacokinetic (Drug)
结局指标
主要结局
Blood Levels of Drug
时间窗: 12 hours
This is the plasma level of the drug as determined by high performance liquid chromatography.
次要结局
未报告次要终点